Clinicopathologic and Prognostic Significance of Transducin-Like Enhancer of Split 1 Protein Expression in Invasive Breast Cancer

다국어 초록 (Multilingual Abstract)

Transducin-like enhancer of split 1 (TLE1) is a member of the TLE family of transcriptional co-repressors that control the transcription of a wide range of genes. We investigated the prognostic significance of TLE1 protein expression in breast cancers by using immunohistochemistry and explored the relationship of TLE1 with clinicopathological parameters. Methods: Immunohistochemistry was performed on 456 cases of breast cancer tiled on tissue microarrays. The relationship between TLE1 expression in normal breast specimens and ductal carcinoma in situ (DCIS) was also analyzed. Results: TLE1 was highly expressed in 57 of 456 (12.5%) carcinoma samples. TLE1 was more frequently expressed in DCIS and invasive breast cancers than in normal breast tissue (p=0.002). High expression of TLE1 significantly correlated with negative lymph node (LN) metastasis (p=0.007), high histologic grade (p<0.001), estrogen receptor negativity (p<0.001), progesterone receptor negativity (p<0.001), human epidermal growth factor receptor 2 (HER2) positivity (p<0.001), and high Ki-67 proliferation index (p<0.001). Based on intrinsic subtypes, high TLE1 expression was strongly associated with HER2+ and triple-negative breast cancers (TNBC) (p<0.001).
Survival analysis demonstrated no significant association between TLE1 expression and disease-free survival (DFS) (p=0.167) or overall survival (OS) (p=0.286). In subgroup analyses, no correlation was found between TLE1 expression and DFS or OS according to LN status or intrinsic subtype. Conclusion: High TLE1 expression is significantly associated with the HER2+ and TNBC subtypes. This is the first study documenting immunohistochemical expression of TLE1 in invasive breast cancer and its association with clinicopathological parameters, prognosis, and intrinsic subtype.

참고문헌 (Reference)

1 Ge C, "miR-942 promotes cancer stem cell-like traits in esophageal squamous cell carcinoma through activation of Wnt/beta-catenin signalling pathway" 6 : 10964-10977, 2015

2 Lakhani SR, "WHO Classification of Tumours of the Breast" International Agency for Research on Cancer 2012

3 Holmes KA, "Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells" 109 : 2748-2753, 2012

4 Ramasamy S, "Tle1 tumor suppressor negatively regulates inflammation in vivo and modulates NF-kappaB inflammatory pathway" 113 : 1871-1876, 2016

5 Pretto D, "The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex" 25 : 3661-3669, 2006

6 Seo SW, "The role of TLE1 in synovial sarcoma" 29 : 1131-1136, 2011

7 Yao X, "The anoikis effector Bit1 displays tumor suppressive function in lung cancer cells" 9 : e101564-, 2014

8 Agarwal M, "The Groucho/transducin-like enhancer of split protein family in animal development" 67 : 472-481, 2015

9 민선영, "The Basic Facts of Korean Breast Cancer in 2013: Results of a Nationwide Survey and Breast Cancer Registry Database" 한국유방암학회 19 (19): 1-7, 2016

10 Yao X, "TLE1promotes EMT in A549 lung cancer cells through suppression of Ecadherin" 455 : 277-284, 2014

11 Brunquell C, "TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells" 10 : 1482-1495, 2012

12 Kosemehmetoglu K, "TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms" 22 : 872-878, 2009

13 Terry J, "TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies" 31 : 240-246, 2007

14 Valente AL, "Specificity of TLE1 expression in unclassified high-grade sarcomas for the diagnosis of synovial sarcoma" 21 : 408-413, 2013

15 Hamidov Z, "Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma" 64 : 990-994, 2011

16 Ciarapica R, "Prolyl isomerase Pin1 and protein kinase HIPK2 cooperate to promote cortical neurogenesis by suppressing Groucho/TLE: Hes1-mediated inhibition of neuronal differentiation" 21 : 321-332, 2014

17 Allred DC, "Prognostic and predictive factors in breast cancer by immunohistochemical analysis" 11 : 155-168, 1998

18 이지혜, "Prognostic and Clinicopathological Significance of Transducer-Like Enhancer of Split 1 Expression in Gastric Cancer" 대한위암학회 16 (16): 21-27, 2016

19 Irshad S, "Molecular heterogeneity of triple-negative breast cancer and its clinical implications" 23 : 566-577, 2011

20 Zhang L, "Micro-RNA-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through nuclear factor kappa B pathways" 57 : 1919-1930, 2013

21 Laporte AN, "Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay" 7 : 34384-34394, 2016

22 Lee HJ, "High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumorinfiltrating lymphocytes in HER2-positive breast cancers" 467 : 701-709, 2015

23 장시형, "High EZH2 Protein Expression Is Associated with Poor Overall Survival in Patients with Luminal A Breast Cancer" 한국유방암학회 19 (19): 53-60, 2016

24 Allen T, "Grg1 acts as a lung-specific oncogene in a transgenic mouse model" 66 : 1294-1301, 2006

25 Jang MH, "Expression of epithelialmesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome" 46 : 1267-1274, 2015

26 Fraga MF, "Epigenetic inactivation of the Groucho homologue gene TLE1in hematologic malignancies" 68 : 4116-4122, 2008